| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 62776 |
DOTA-GSG-KCCYSL DOTA缀合物ErbB-2靶向肽KCCYSL |
138 |
h |
2024-12-19 |
| 62777 |
MC-MMAF ， cas:863971-19-1，ADC定制 |
104 |
wyh |
2024-12-19 |
| 62778 |
TCO-PEG4-Fmoc-Gly-Gly-Gly-ADC连接子 |
127 |
zyl |
2024-12-19 |
| 62779 |
模拟肽4-[2-(3,4,5,6-四氢嘧啶-2-基氨基)乙氧基]苯甲酰基-2-[N-(3-氨基-新戊-1-氨基甲酰基)]-氨乙基磺酰基-氨基-β-丙氨酸(IAC)缀合DOTA |
77 |
h |
2024-12-19 |
| 62780 |
DOTA-chCE7 DOTA标记的糖基化单克隆抗L1-CAM抗体chCE7 |
91 |
h |
2024-12-19 |
| 62781 |
Vc-MMAE， cas:646502-53-6，ADC定制 |
109 |
wyh |
2024-12-19 |
| 62782 |
Azido-PEG4-MMAE |
107 |
zyl |
2024-12-19 |
| 62783 |
cas:2055024-59-2，Fmoc-PEG2-Val-Cit-PAB-OH |
106 |
zyl |
2024-12-19 |
| 62784 |
Azide-PEG6-Val-Cit-PAB-PEG6- Biotin，ADC定制 |
108 |
wyh |
2024-12-19 |
| 62785 |
Ga-DOTA-(Asp)n 大环DOTA共轭(Asp)n肽 |
64 |
h |
2024-12-19 |
| 62786 |
cas:1807530-16-0，2-hydroxyethyl disulfide mono-Tosylate- ADC linker |
79 |
zyl |
2024-12-19 |
| 62787 |
DOTA偶联受体特异性肽 |
109 |
h |
2024-12-19 |
| 62788 |
聚乙二醇化DOTA-AHA基GdIII螯合物 PEGylated DOTA-based gadolinium(III) |
85 |
h |
2024-12-19 |
| 62789 |
PAMAM树状大分子DOTA缀合物 PAMAM–DOTA |
89 |
h |
2024-12-19 |
| 62790 |
ALD-tetra-EG-Osu的介绍 |
104 |
zyl |
2024-12-19 |
| 62791 |
SSTR2靶向肽Tyr(3)-奥曲肽(tate) |
190 |
h |
2024-12-19 |
| 62792 |
DOTA-D-Phe(1)-Tyr(3)-Octreotide |
83 |
h |
2024-12-19 |
| 62793 |
cas:55750-63-5，Mal-heptanoic NHS ester |
101 |
zyl |
2024-12-19 |
| 62794 |
DOTA-Fab-PEG24-EGF DOTA-PEG修饰曲妥珠单抗Fab片段偶联表皮生长因子 |
85 |
h |
2024-12-19 |
| 62795 |
cas:663599-10-8，DMAC-SPP |
95 |
zyl |
2024-12-19 |
| 62796 |
多甲基化的1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)配体 |
134 |
h |
2024-12-19 |
| 62797 |
PEG-pGlu(DOTA)8-LA4 |
47 |
h |
2024-12-19 |
| 62798 |
cas:937025-17-7，2,5-Dioxopyrrolidin-1-yl 2-oxo-6,9,12,15-tetraoxa-3-thiaoctadecan-18-oate |
135 |
zyl |
2024-12-19 |
| 62799 |
DOTA-Hyd-TRP PET示踪剂 |
91 |
h |
2024-12-19 |
| 62800 |
Ga-DOTATOC Ga-DOTA-D-Phe-Tyr-奥曲肽 |
125 |
h |
2024-12-19 |
| 62801 |
cas:1226371-65-8，N-(2-(2,5-Dimethylphenoxy)ethyl)-4-formylbenzamide |
70 |
zyl |
2024-12-19 |
| 62802 |
DOTA-ALN DOTA-阿仑膦酸盐 |
71 |
h |
2024-12-19 |
| 62803 |
氨氯地平DOTA偶联物 DOTA-Amlodipine |
129 |
h |
2024-12-19 |
| 62804 |
cas:906564-59-8，Propargyl-C2-NHS ester |
91 |
zyl |
2024-12-19 |
| 62805 |
DOTA-Gp2-EGFR DOTA螯合剂标记结合表皮生长因子受体EGFR靶向Gp2 |
78 |
h |
2024-12-19 |
| 62806 |
cas:894095-98-8，β-D-glucuronide-pNP-carbonate |
70 |
zyl |
2024-12-19 |
| 62807 |
DOTA结合肽功能化金纳米粒子 |
81 |
h |
2024-12-19 |
| 62808 |
90Y-DOTA-Bn 钇-90-DOTA-铃蟾肽 |
100 |
h |
2024-12-19 |
| 62809 |
cas:85916-13-8，NH-bis(C1-Boc)，亚氨基二乙酸二异丁酯 |
94 |
zyl |
2024-12-19 |
| 62810 |
Anti-CD19 (clone huB4)-Mc-MMAF-ADC分子 |
62 |
zyl |
2024-12-19 |
| 62811 |
Boc-Val-Cit-PAB-PNP cas:870487-10-8 |
62 |
zyl |
2024-12-19 |
| 62812 |
cas:2353409-70-6 MMAF-methyl ester |
103 |
zyl |
2024-12-19 |
| 62813 |
DOTA-ipilimumab 螯合剂DOTA缀合单克隆抗体ipilimumab |
74 |
h |
2024-12-19 |
| 62814 |
双功能单膦酸Ln-DOTA衍生物 |
97 |
h |
2024-12-19 |
| 62815 |
Cu-DOTA-阿伦膦酸盐 Cu-DOTA-alendronate |
94 |
h |
2024-12-19 |
| 62816 |
Mc-3377的介绍 |
76 |
zyl |
2024-12-19 |
| 62817 |
Endo-BCN-PEG4-Val-Cit-PAB-MMAF的介绍 |
76 |
zyl |
2024-12-19 |
| 62818 |
(DOTA)n-PAMAM-[尼妥珠单抗-F(ab’)2]的缀合物 |
74 |
h |
2024-12-19 |
| 62819 |
cas:2055041-39-7 Mal-PEG4-Val-Cit-PAB-OH |
109 |
zyl |
2024-12-19 |
| 62820 |
DBCO-PEG3-Val-Cit-PAB-PNP的介绍 |
126 |
zyl |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询